New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
09:21 EDTFEYE, PIR, MRK, BBBY, IMPV, RT, HPQ, QLYS, EBAY, CSH, RADOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Rite Aid (RAD), up 13%... Ruby Tuesday (RT), up 7%... Pier 1 Imports (PIR), up 4%. ALSO HIGHER: Merck (MRK), up 1.5% after announcing data from C-WORTHy study... Cash America (CSH), up 15% after earnings report, announcing plans to evaluate separation of online business... HP (HPQ), up 1.7% after initiated with a Buy at Deutsche Bank. DOWN AFTER EARNINGS: Bed Bath & Beyond (BBBY), down 5.3%. ALSO LOWER: EBAY (EBAY), down 1% after settling proxy contest with Carl Icahn, who withdrew his PayPal spin-off proposal... Imperva (IMPV), down 35% after slashing its first quarter profit and sales outlook, shares downgraded at Deutsche Bank and Oppenheimer. Several of its security software peers are lower in pre-market trade as well, including FireEye (FEYE), which is down 3%, and Qualys (QLYS), which is down 1.5%.
News For EBAY;IMPV;FEYE;QLYS;BBBY;RAD;HPQ;MRK;CSH;RT;PIR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
May 14, 2015
17:36 EDTEBAYeBay, PayPal separation remains on-track to be completed in Q3
17:35 EDTEBAYPayPal names board following separation from eBay
Subscribe for More Information
17:33 EDTEBAYeBay names board following separation from PayPal
Subscribe for More Information
14:30 EDTEBAYPayPal to trade on Nasdaq with symbol 'PYPL' after separation completed
Subscribe for More Information
14:01 EDTFEYEFireEye currently unwilling to consider sale, Re/code reports
After Cisco (CEO) John Chambers said last night on the company Q3 conference call that he "wouldn't bet on" the rumor that his company was targeting an acquisition of FireEye (FEYE), Re/code's Arik Hesseldahl added that FireEye is not for sale in any case. The security company's management would not be willing to entertain takeover offers before it reaches $1B in annual revenue, sources familiar with the matter told Hesseldahl. Reference Link
09:40 EDTHPQHP upgraded to Buy from Hold at Cross Research
Subscribe for More Information
09:22 EDTMRKLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:21 EDTFEYEFinjan says patent suits ongoing with numerous cybersecurity companies
Finjan (FNJN) said it has an active Markman Hearing schedule with two Markman Hearings already concluded in favor of the company and two additional Markman Hearings to be held in Q2. The company has a two-week trial against Blue Coat set to commence on July 20. Finjan has patent infringement lawsuits against FireEye (FEYE), BlueCoat, Proofpoint (PFPT), Sophos, Symantec (SYMC), and Palo Alto Networks (PANW) relating to, collectively, more than 20 patents in the Finjan portfolio. Subsequent to the quarter end, Finjan entered into a negotiated license agreement with F-Secure Corporation, a company incorporated in Finland. The agreement provides for F-Secure to pay Finjan the sum of $1M in cash, to be paid in two installments, consisting of $700,000 which was received on April 22 and $300,000 on or before March 31, 2016. The agreement also provides for the assignment by F-Secure to Finjan of two patents, U.S. Patent Nos. 8,474,048 and 7,749,991.
07:56 EDTIMPVImperva outlook has improved, says RBC Capital
After marketing with Imperva's management, RBC Capital is more upbeat on the company's outlook. The firm thinks Imperva's management looks confident, while its end market has improved and it remains well-positioned within the sector. RBC keeps a $61 price target and Outperform rating on the shares.
06:46 EDTIMPVImperva price target raised to $66 from $57 at Piper Jaffray
Piper Jaffray raised its price target for Imperva to $66 after meetings with management gave it increased conviction in the company's Q2 results as well as its longer-term belief that the company is one of the best positioned vendors. Piper views the stock's valuation as "relatively cheap" and reiterates an Overweight rating on the name.
06:15 EDTHPQHP Q2 sales weakness largely expected, says Citigroup
Citigroup believes HP's Q2 revenue on May 21 could miss the consensus expectation of $25.8B due to PC weakness and currency pressure. Citi thinks sales weakness is largely expected, however. The firm says HP shares "will start to work again" as management will likely address and quantify the additional costs of operating as two separate companies. Uncertainty around the size of the dis-synergy costs has been a key factor behind the stock's recent underperformance, Citi believes. It keeps a Buy rating on HP with a $41 price target.
May 13, 2015
18:33 EDTMRKMerck to present new Keytruda data on 10 types of cancer at 2015 ASCO meeting
Subscribe for More Information
18:04 EDTFEYECisco CEO says don't bet on talk of FireEye acquisition
Subscribe for More Information
13:12 EDTMRKSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
12:43 EDTHPQHewlett-Packard volatility elevated into Q2 and outlook
Subscribe for More Information
10:32 EDTFEYEFireEye calls active on renewed takeover chatter
Subscribe for More Information
10:20 EDTFEYERumor: FireEye moves up on renewed takeover chatter
Subscribe for More Information
07:21 EDTQLYSCredit Suisse to hold a conference
4th Annual Disruptive Technology Conference is being held in San Francisco on May 13-14 with webcasted company presentations to begin on May 13 at 10:35 am; not all company presentations may be webcasted. Webcast Link
May 12, 2015
13:13 EDTMRKExpert says Norway biosimilar case an 'outlier,' CT Financial News reports
Subscribe for More Information
06:09 EDTMRKThreshold announces Merck receives FDA Fast Track designation for evofosfamide
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use